Cardiac Catheterization Laboratory 2014, The Heart Centre, Rigshospitalet, Copenhagen University Hospital and Faculty of Health Sciences, DK-2100 Copenhagen, Denmark.
Biomark Med. 2010 Aug;4(4):591-600. doi: 10.2217/bmm.10.58.
Cardiovascular disease in the form of coronary artery disease is the most common cause of death in western countries. Early treatment with stabilizing drugs and mechanical revascularization by percutaneous coronary intervention or coronary bypass surgery has reduced the mortality significantly. But in spite of improved treatments, many patients are still plagued by a high frequency of angina symptoms, hospitalizations and a poor prognosis. There is a need for new independent or supplementary biomarkers that can help to predict cardiovascular disease and cardiovascular events earlier and more precisely, and thus accompany existing biomarkers in both primary and secondary cardiovascular prevention. One such potential new biomarker is the protein YKL-40. As an independent biomarker in both cardiovascular diseases and noncardiovascular diseases, current evidence suggests YKL-40 to be most useful as a marker of disease severity, prognosis and short survival. However, future studies will evaluate whether YKL-40 can be used for monitoring of the treatment effect in different patient populations with a distinct disease diagnosis. In this article we explore present knowledge on YKL-40 as a biomarker in cardiovascular disease.
心血管疾病以冠状动脉疾病的形式是西方国家最常见的死亡原因。早期使用稳定药物和经皮冠状动脉介入或冠状动脉旁路手术进行机械血运重建，大大降低了死亡率。但尽管治疗有所改善，许多患者仍饱受心绞痛症状频繁发作、住院和预后不良的困扰。需要新的独立或补充生物标志物，以帮助更早、更准确地预测心血管疾病和心血管事件，从而在一级和二级心血管预防中与现有生物标志物一起使用。一种潜在的新型生物标志物是蛋白 YKL-40。作为心血管疾病和非心血管疾病的独立生物标志物，目前的证据表明 YKL-40 作为疾病严重程度、预后和短期生存的标志物最有用。然而，未来的研究将评估 YKL-40 是否可用于监测不同疾病诊断的不同患者人群的治疗效果。本文探讨了 YKL-40 作为心血管疾病生物标志物的现有知识。
